These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 34360855)

  • 1. Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia.
    Seipel K; Graber C; Flückiger L; Bacher U; Pabst T
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia.
    Seipel K; Brügger Y; Mandhair H; Bacher U; Pabst T
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia.
    Seipel K; Kopp B; Bacher U; Pabst T
    Cancers (Basel); 2021 Feb; 13(3):. PubMed ID: 33540760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale for a Combination Therapy Consisting of MCL1- and MEK-Inhibitors in Acute Myeloid Leukemia.
    Seipel K; Schmitter K; Bacher U; Pabst T
    Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31718075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FLT3 and IRAK4 Inhibitor Emavusertib in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia.
    Seipel K; Mandhair H; Bacher U; Pabst T
    Curr Issues Mol Biol; 2024 Mar; 46(4):2946-2960. PubMed ID: 38666914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HSP90 Inhibitor PU-H71 in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia.
    Seipel K; Kohler S; Bacher U; Pabst T
    Curr Issues Mol Biol; 2023 Aug; 45(9):7011-7026. PubMed ID: 37754227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
    Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
    Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
    Kim M; Williams S
    Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin synergizes with gilteritinib in treating FLT3-mutated leukemia via targeting PLK1 signaling.
    Chen M; Shen C; Chen Y; Chen Z; Zhou K; Chen Y; Li W; Zeng C; Qing Y; Wu D; Xu C; Tang T; Che Y; Qin X; Xu Z; Wang K; Leung K; Sau L; Deng X; Hu J; Wu Y; Chen J
    Cell Rep Med; 2024 Jul; 5(7):101645. PubMed ID: 39019012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).
    Kindler T; Breitenbuecher F; Kasper S; Estey E; Giles F; Feldman E; Ehninger G; Schiller G; Klimek V; Nimer SD; Gratwohl A; Choudhary CR; Mueller-Tidow C; Serve H; Gschaidmeier H; Cohen PS; Huber C; Fischer T
    Blood; 2005 Jan; 105(1):335-40. PubMed ID: 15345593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDM2- and FLT3-inhibitors in the treatment of
    Seipel K; Marques MAT; Sidler C; Mueller BU; Pabst T
    Haematologica; 2018 Nov; 103(11):1862-1872. PubMed ID: 29976747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3.
    Bali P; George P; Cohen P; Tao J; Guo F; Sigua C; Vishvanath A; Scuto A; Annavarapu S; Fiskus W; Moscinski L; Atadja P; Bhalla K
    Clin Cancer Res; 2004 Aug; 10(15):4991-7. PubMed ID: 15297399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3.
    Lu H; Weng XQ; Sheng Y; Wu J; Xi HM; Cai X
    BMC Cancer; 2022 Jul; 22(1):749. PubMed ID: 35810308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3.
    Spiekermann K; Dirschinger RJ; Schwab R; Bagrintseva K; Faber F; Buske C; Schnittger S; Kelly LM; Gilliland DG; Hiddemann W
    Blood; 2003 Feb; 101(4):1494-504. PubMed ID: 12406902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.
    George P; Bali P; Cohen P; Tao J; Guo F; Sigua C; Vishvanath A; Fiskus W; Scuto A; Annavarapu S; Moscinski L; Bhalla K
    Cancer Res; 2004 May; 64(10):3645-52. PubMed ID: 15150124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.
    Weisberg E; Liu Q; Nelson E; Kung AL; Christie AL; Bronson R; Sattler M; Sanda T; Zhao Z; Hur W; Mitsiades C; Smith R; Daley JF; Stone R; Galinsky I; Griffin JD; Gray N
    Leukemia; 2012 Oct; 26(10):2233-44. PubMed ID: 22469781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
    Fischer T; Stone RM; Deangelo DJ; Galinsky I; Estey E; Lanza C; Fox E; Ehninger G; Feldman EJ; Schiller GJ; Klimek VM; Nimer SD; Gilliland DG; Dutreix C; Huntsman-Labed A; Virkus J; Giles FJ
    J Clin Oncol; 2010 Oct; 28(28):4339-45. PubMed ID: 20733134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic inhibition of STAT5 in acute myeloid leukemia.
    Wingelhofer B; Maurer B; Heyes EC; Cumaraswamy AA; Berger-Becvar A; de Araujo ED; Orlova A; Freund P; Ruge F; Park J; Tin G; Ahmar S; Lardeau CH; Sadovnik I; Bajusz D; Keserű GM; Grebien F; Kubicek S; Valent P; Gunning PT; Moriggl R
    Leukemia; 2018 May; 32(5):1135-1146. PubMed ID: 29472718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.
    Nogami A; Oshikawa G; Okada K; Fukutake S; Umezawa Y; Nagao T; Kurosu T; Miura O
    Oncotarget; 2015 Apr; 6(11):9189-205. PubMed ID: 25826077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
    Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
    Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.